Barclays Boosts Aveanna Healthcare (NASDAQ:AVAH) Price Target to $9.50

Aveanna Healthcare (NASDAQ:AVAH) had its price objective increased by research analysts at Barclays from $9.00 to $9.50 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target suggests a potential downside of 2.06% from the company’s current price.

Several other brokerages have also commented on AVAH. Stephens raised Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $10.00 to $11.00 in a research note on Friday, May 15th. BMO Capital Markets dropped their price target on shares of Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, March 20th. Raymond James Financial raised Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 price objective for the company in a research report on Friday, March 20th. Royal Bank Of Canada raised Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Aveanna Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $10.56.

Aveanna Healthcare Stock Down 1.2%

Shares of AVAH stock opened at $9.70 on Thursday. The stock has a market cap of $2.11 billion, a P/E ratio of 8.22, a P/E/G ratio of 0.98 and a beta of 1.89. Aveanna Healthcare has a twelve month low of $3.73 and a twelve month high of $10.32. The stock has a 50 day moving average of $7.66 and a 200 day moving average of $7.59. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 5.35.

Aveanna Healthcare (NASDAQ:AVAH) last posted its earnings results on Thursday, May 14th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.05. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. The business had revenue of $647.91 million for the quarter, compared to analyst estimates of $613.22 million. The firm’s revenue was up 15.9% on a year-over-year basis. As a group, sell-side analysts expect that Aveanna Healthcare will post 0.68 EPS for the current year.

Insider Buying and Selling at Aveanna Healthcare

In other Aveanna Healthcare news, insider Patrick A. Cunningham sold 125,000 shares of Aveanna Healthcare stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $7.59, for a total value of $948,750.00. Following the transaction, the insider owned 212,755 shares in the company, valued at $1,614,810.45. This trade represents a 37.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Robert M. Williams, Jr. sold 3,000,000 shares of Aveanna Healthcare stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $8.01, for a total value of $24,030,000.00. Following the completion of the transaction, the insider directly owned 190,130 shares in the company, valued at $1,522,941.30. This represents a 94.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,305,664 shares of company stock valued at $215,555,910 over the last three months. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its holdings in Aveanna Healthcare by 21.2% during the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock worth $142,000 after acquiring an additional 4,602 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Aveanna Healthcare by 8.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock valued at $1,842,000 after acquiring an additional 25,974 shares during the period. Jane Street Group LLC grew its position in Aveanna Healthcare by 522.0% in the 1st quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after buying an additional 63,010 shares in the last quarter. Creative Planning increased its stake in shares of Aveanna Healthcare by 15.1% during the second quarter. Creative Planning now owns 47,025 shares of the company’s stock valued at $246,000 after acquiring an additional 6,171 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Aveanna Healthcare by 65.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 158,265 shares of the company’s stock valued at $828,000 after purchasing an additional 62,348 shares during the period. 87.96% of the stock is currently owned by hedge funds and other institutional investors.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.